

New oncology reimbursements in Belgium

P. Specenier, MD, PhD¹

Overview of Belgian reimbursement news

(Belg J Med Oncol 2015;9(5):202)

Stivarga® (regorafenib)

Stivarga can be reimbursed for the treatment of patients with a metastatic colorectal cancer progressing during or after a treatment with a fluoropyrimidine and a VEGF- and/or EGFR-directed therapy, or in case the patient is not eligible for these therapies due to a medical condition, and for the treatment of patients with non-resectable or metastatic gastrointestinal stromal tumour with progression or intolerant to imatinib and sunitinib.

Imbruvica® (ibrutinib)

Imbruvica is reimbursable for patients with chronic lymphocytic leukaemia:

- with 17p-deletion or TP53-mutation,
- after at least one treatment regimen containing a CD20-directed monoclonal antibody or
- after at least two prior treatment regimens and

for the treatment of recurrent or refractory mantle cell lymphoma after at least one prior standard treatment regimen.

Avastin® (bevacizumab)

Avastin can be reimbursed in combination with paclitaxel, topotecan or pegylated doxorubicin, for the treatment of recurrent platinum-resistant epithelial ovarian cancer after no more than two prior treatment regimens for patients who did not receive a prior VEGF-directed therapy.

Perjeta® (pertuzumab)

The European Commission (EC) has approved the use of Perjeta® (pertuzumab) in combination with Herceptin® (trastuzumab) and chemotherapy for the neoadjuvant treatment (use before surgery) of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence (eBC). The Perjeta® regimen is the first neoadjuvant breast cancer treatment approved by the EC based on pCR (pathological complete response), a clinical endpoint that has allowed Perjeta® to be made available to people with this aggressive disease faster than under typical processes.

¹Department of Oncology, University Hospital Antwerp, Edegem, Belgium.

Please send all correspondence to: T. Feys, MSc, MBA, Ariez International, Oude Houtlei 118, 9000 Ghent, Belgium, email: t.feys@ariez.com.

Conflict of interest: The author has nothing to disclose and indicates no potential conflict of interest.